[Study of the delayed-action form of a synthetic antiparkinsonian drug: Akineton].
D000433:1-Propanol; D000293:Adolescent; D000328:Adult; D000978:Antiparkinson Agents / Q000008:administration & dosage*; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000188:drug therapy; D001712:Biperiden / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002389:Catatonia / Q000188:drug therapy; D003692:Delayed-Action Preparations; D005116:Extrapyramidal Tracts / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010259:Paranoid Disorders / Q000188:drug therapy; D010880:Piperidines / Q000008:administration & dosage*; D011618:Psychotic Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy*; D012562:Schizophrenia, Disorganized / Q000188:drug therapy; D014149:Tranquilizing Agents / Q000009:adverse effects / Q000627:therapeutic use; D014202:Tremor / Q000188:drug therapy
D000978:Antiparkinson Agents; D003692:Delayed-Action Preparations; D010880:Piperidines; D014149:Tranquilizing Agents; D001712:Biperiden; D000433:1-Propanol
Etude de la forme retard d'un antiparkinsonien de synthèse: l'Akineton.